MIRA Pharmaceuticals, Inc. (MIRA) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
Analysts estimate Earnings Per Share (EPS) of $-0.55 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.51 vs est $-0.55 (beat +7.8%). 2025: actual $-1.35 vs est $-1.17 (missed -15.4%). Analyst accuracy: 89%.
MIRA Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to MIRA Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — MIRA
89%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.51
vs Est –$0.55
▲ 8.5% off
2025
Actual –$1.35
vs Est –$1.17
▼ 13.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — MIRA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
